Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: The OFELY study

Osteoporosis International

Volumn 24, Issue 2, 2013, Pages 489-494

  Garnero, P ^a,b   Sornay Rendu, E ^a   Munoz, F ^a   Borel, O ^a   Chapurlat, R D ^a  

^a INSERM   (France)

^b Cisbio Bioassays ^*  (France)

Author keywords

Bone markers; Fracture; Osteoporosis; PTH; Sclerostin

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; PARATHYROID HORMONE; SCLEROSTIN; TESTOSTERONE;

AGED; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; FRACTURE; HIP; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SPINE; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENETIC MARKERS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PARATHYROID HORMONE; RISK ASSESSMENT;

EID: 84873726062     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-1978-x     Document Type: Article

References (30)

1. Bonewald LF (2011) The amazing osteocytes. J Bone Miner Res 26:229-238
2. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CWGM (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814
3. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887
4. Poole KE, van Bezooijen RL, Loverridge N et al (2005) Sclerostin is a delayed product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844
5. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583
6. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148-158
7. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Vito M, Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269
8. Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2009) Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189
9. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
10. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948-59
11. Padhi D, Graham J, Stouch B, Liang F, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26
12. Mc Nulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R (2011) Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. Clin Endocrinol Metab 96:E1159-E1162
13. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaret-Castro M, Silverberg SJ, Bilezikian JP (2011) Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 96:3804-10
14. Kirmani S, Moedder UK, Hoey K, Peterson J, McCready L, Shreyasee Amin SL, Melton J, Riggs JB, Ralph Muller R, Khosla S (2010) Gender differences in circulating sclerostin levels are established during puberty and correlate with cortical porosity. J Bone Miner Res 21(Suppl 1):S54
15. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-7
16. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Lawrence Riggs B, Joseph Melton L 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373-379
17. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2010) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27-34
18. Drake MT, Srinivasan R, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
19. olyzos SA, Anastasolakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2011) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 23(3):1171-1176
20. Ardawi MS, Al-Kadi HA, Rouzzi AA, Qari MH (2011) Determinants of serum sclerostin in healthy pre and postmenopausal women. J Bone Miner Res 26:2812-2822
21. Eastell R, Hannon R, Gossiel F. (2010). Regulators of bone formation in postmenopausal osteoporosis: effect of bisphosphonate treatment. J Bone Miner Res 26(Suppl 1): S31
22. Gossiel F, Lane N, Eastell R (2011). The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with PTH. J Bone Miner Res 26(Suppl 1): S80
23. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD (1997) Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 12:683-690
24. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349
25. Genant HK, Wu CY, Van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
26. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148-158
27. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller (2007) Control of the SOST enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957-1967
28. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ (2011) Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrin Metab 96:E1848-E1851
29. Santosh SNH, Joseph F, Hamilton A, Durham B, Robinson A, Tang J, Voras JP, Fraser D (2011) Circulating sclerostin demonstrates a circadian rhythm in young healthy men. J Bone Miner Res 26(Suppl 1): SU389
30. Arasu A, Xawthon PM Do T, Arora PS, Lui L-Y, Cauley JA, Ebsrud KE, Cummings SR. (2011) Sclerostin and risk of hip fracture in older women. J Bone Miner Res 26:S143